Skip to main content

Table 1 Baseline characteristics of the study population (mean ± SEM)

From: Chronic TNF-α Neutralization Does Not Improve Insulin Resistance or Endothelial Function in “Healthy” Men with Metabolic Syndrome

 

Infliximab

Placebo

P

N

5

4

 

Age (years)

40 ± 2

38 ± 3

nsa

BMI (kg/m2)

31.9 ± 0.6

31.4 ± 1.1

ns

Waist (cm)

111 ± 4

107 ± 7

ns

BP syst. (mmHg)

142 ± 4

138 ± 5

ns

BP diast. (mmHg)

94 ± 4

87 ± 2

ns

FPGb (mmol/L)

5.7 ± 0.4

5.4 ± 0.2

ns

Fasting insulin (µU/L)

15.9 ± 3.5

15.2 ± 2.7

ns

HOMA index

4.2 ± 1.2

3.7 ± 0.8

ns

Cholesterol (mmol/L)

6.3 ± 0.8

6.9 ± 0.9

ns

LDL-C (mmol/L)

2.5 ± 0.4

3.4 ± 1

ns

HDL-C (mmol/L)

± 0.1

± 0.1

ns

Triglycerides (mmol/L)

5.9 ± 1.8

6.0 ± 1.6

ns

  1. ans: not significant.
  2. bFPG: fasting plasma glucose.